In adolescent patients with sickle cell disease, hydroxycarbamide therapy was associated with improvements in neurocognition variables such as working memory, verbal memory, and nonverbal IQ, ...
May 13, 2011 — Hydroxycarbamide can be considered for treatment of all very young children with sickle cell anemia, according to the results of a randomized, double-blind trial reported in the May 14 ...
Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study After a median ...
The first randomised double-blind trial to examine the effect of hydroxycarbamide (previously hydroxyurea) in very young children with sickle-cell anaemia shows that the drug is safe and significantly ...
The European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use recommended granting marketing authorization for hydroxycarbamide (Xromi, Nova Laboratories Ireland Limited) for ...
The new formation will enable doctors to personalise doses for young children. Nova Laboratories has announced details of its “revolutionary” new liquid formation of hydroxycarbamide for sickle cell ...
Polycythaemia vera is a condition in which the bone marrow makes too many red blood cells. It is one of a group of conditions called myeloproliferative disorders. It is closely related to leukaemia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results